Coordinating Merger-control Filings for Multi-jurisdictional Cross-border M&A Involving India (2026)

Who this is for: in-house counsel, private equity sponsors, deal teams and external counsel planning multi-jurisdictional combinations that may require a filing before the Competition Commission of India. This guide is practical and execution-oriented, covering sequencing, documentation, remedies and gun-jumping mitigation in 2026.

Introduction: why coordination matters in 2026

Merger control filings india now sit at the centre of nearly every significant multi-jurisdiction transaction, and in 2026 the coordination challenge has sharpened considerably. Competition authorities are applying their rules with increasing extraterritorial reach, parallel filings across the Competition Commission of India (CCI), the European Commission, the US agencies and the UK Competition and Markets Authority (CMA) have become routine, and authorities increasingly expect remedies to be tailored to local markets. For deal teams, the practical consequence is that timing, harmonised documentation and remedy portability are no longer back-office tasks, they are deal-critical variables that determine whether a transaction closes on schedule.

The purpose of this guide is to provide a partner-level, India-specific playbook for coordinating merger control filings india alongside filings in other major jurisdictions. We set out when an Indian filing is triggered, how to sequence filings intelligently, how to build a single harmonised disclosure bundle, how to approach remedies with the CCI, and how to manage the real-world risk of gun-jumping. Throughout, we point to primary regulatory sources so that the strategy rests on verifiable rules rather than assumption.

This is general guidance and not legal advice. Every combination turns on its own facts, and the interaction between competition clearance, FDI policy and sectoral approvals in India requires specialist review before any filing strategy is locked in.

When will India require a merger-control filing?

The first question for any deal team is whether the transaction requires a notification to the CCI at all. India operates a mandatory, suspensory regime: qualifying combinations must be notified and cannot be consummated until the CCI has cleared them. Determining whether a cross-border transaction falls within that net is where a disciplined approach to merger control filings india begins.

CCI thresholds and calculation

Under the Competition Act, 2002 and the combination regulations administered by the CCI, a transaction is notifiable where the parties, or the group to which they belong, exceed prescribed asset and turnover thresholds. These thresholds are tested at two levels: the parties to the combination (the enterprise level) and the wider group. The calculation aggregates both domestic and global assets and turnover, with specific rules for how much of that figure must have an Indian nexus.

Because the thresholds are periodically revised and are subject to exemptions (including the “de minimis”/small-target exemption notified by the Central Government), deal teams should verify the current figures directly against the CCI’s published regulations and the relevant government notifications before concluding that a filing is or is not required.

The Competition (Amendment) Act, 2023 also introduced a deal-value threshold for transactions above a specified consideration where the target has substantial business operations in India, alongside revised timelines and procedures brought into effect through the CCI’s combination regulations. Deal teams should confirm the current position directly against the CCI’s notified rules, as the implementing framework continues to evolve.

The practical point for cross-border transactions is that a deal with only modest Indian revenue can still be caught if the parties are large globally, or where the deal-value threshold applies. The attribution of worldwide turnover and assets means that a transaction negotiated and closed entirely outside India can nonetheless require clearance here. This is why an early threshold assessment, ideally before the term sheet is signed, is indispensable.

Attribution rules for global deals

Attribution rules determine whose assets and turnover count towards the thresholds, and they are frequently misunderstood in global structures. The analysis follows control: the acquirer’s entire group, not just the immediate buying entity, is typically brought into the calculation. For private equity sponsors, this means the turnover and assets of portfolio companies within the same control structure may be aggregated, which can push an otherwise sub-threshold deal into notifiable territory.

Minority acquisitions require particular care. Not every minority stake triggers a filing, but acquisitions that confer material influence, board rights or other indicia of control can be caught even where the headline equity percentage looks modest. Where a transaction sits close to the control line, deal teams should document the rationale for their notifiability conclusion contemporaneously, because that reasoning may need to be defended if the CCI later queries whether a filing should have been made.

Extraterritorial triggers and practice points

The extraterritorial reach of Indian merger control is the feature most likely to surprise overseas deal teams. A combination between two foreign entities, signed and closed abroad, can still require a CCI filing where the transaction has, or is likely to have, an appreciable adverse effect on competition within India. The decisive factor is the Indian nexus: sales into India, assets located in India, or the acquisition of a business that supplies the Indian market.

The practice points that follow are straightforward but often overlooked. First, run the threshold test on a group-wide, worldwide basis rather than looking only at the target’s local footprint. Second, map every line of business that touches India, including sales made through distributors or online channels. Third, where the answer is genuinely borderline, consider a pre-filing consultation with the CCI so that its view is understood before closing timetables are fixed. Getting the trigger analysis wrong is the single most common cause of avoidable delay in merger control filings india.

Sequencing filings between India and other jurisdictions, practical frameworks

Once notifiability is confirmed across the relevant jurisdictions, the central strategic question becomes sequencing. Effective CCI filing coordination is rarely about filing everywhere at once; it is about ordering filings so that the slowest or most demanding authority does not derail the whole timetable, and so that remedies negotiated in one forum can inform, rather than contradict, those sought elsewhere.

Key sequencing factors

Several factors drive the sequencing decision in multi-jurisdiction merger filings:

• Market overlap. Where the competitive concerns are concentrated in one jurisdiction, that authority is likely to be the critical-path regulator whose timetable dictates the deal.
• Time-sensitive remedies. If a divestiture or behavioural undertaking is likely, the authority most insistent on remedies should be engaged early so the remedy package can be designed once and adapted for other forums.
• Risk appetite. Buyers with low tolerance for closing risk may prefer to secure the hardest clearance first; those prioritising speed may file in parallel and manage the risk of divergent outcomes.
• Information asymmetry. Filing first in a jurisdiction with extensive disclosure obligations produces a documentary record that other authorities may request, so the order of filing affects what becomes discoverable.

Four sequencing models for merger control filings india

In practice, deal teams choose between four broad sequencing models when coordinating merger control filings india with other authorities:

• Parallel filing. All notifications are submitted at or around the same time. This minimises the overall timeline and is suited to deals with limited competitive concern. The downside is that the parties lose the ability to let one authority’s analysis shape another’s, and divergent information requests must be managed simultaneously.
• Staggered filing. Filings are spaced so that the lead authority’s review is well advanced before others begin. This allows learning from the first review but extends the overall clock and requires careful management so that no single authority’s timetable expires while others are pending.
• Lead-authority model. One regulator, usually the one with the most significant overlap, is treated as the primary forum, with its remedy package serving as the template for secondary filings. This produces coherence across jurisdictions but creates dependency on the lead authority’s pace.
• Back-loaded filing. India, or another jurisdiction, is filed last once the shape of the global clearance is clear. This can be efficient where the Indian concern is modest, but it risks the Indian review becoming the final bottleneck if the CCI raises unexpected queries.

No single model is correct for every deal. The sequencing choice should be revisited as the competitive analysis matures, because what looked like a minor overlap at signing can become the critical path once an authority opens a deeper probe.

Country-specific considerations

Short practical observations on the principal jurisdictions that interact with Indian filings:

• European Union. The European Commission operates a one-stop-shop for concentrations with an EU dimension and runs defined statutory phases. Its remedy practice is sophisticated and its decisions are frequently treated as a reference point by other authorities.
• United States. The Hart-Scott-Rodino regime is notification-and-waiting-period based, with a defined initial waiting period that can be extended by a second request. US remedies tend to focus on the US market.
• United Kingdom. The CMA runs a two-phase process with statutory timescales and takes an independent view on remedies suitable for the UK market.

For deal teams coordinating merger control filings india across these forums, the OECD’s comparative guidance on merger review and best practice is a useful reference for understanding how authorities approach sequencing and remedy coordination.

Comparison table: filing sequencing and typical timelines

The table below sets out indicative triggers, timelines and remedy-portability positions across India, the EU, the US and the UK. All timelines are indicative only and are subject to statutory extensions, information requests and the stopping of clocks; verify current positions against the regulator sources listed at the end of this article.

The practical lesson from the matrix is that no two regimes run on the same clock or apply the same remedy philosophy. A sequencing plan built on the assumption that clearances will arrive together is fragile; one built around the slowest likely critical-path authority is resilient.

Harmonised documentation and disclosure bundles for India

The documentary burden of a multi-jurisdiction combination is substantial, and the most efficient teams build a single master evidence base from which each jurisdictional filing is assembled. Done well, this harmonised approach reduces cost, ensures consistency across filings, and prevents the embarrassing and sometimes damaging situation where the same transaction is described differently to different regulators.

What to include in a CCI bundle

A well-constructed Indian filing bundle typically contains:

• Organisational charts. Pre- and post-transaction structures showing control at group level, so the CCI can see exactly which entities are party to the combination.
• Turnover and asset schedules. Figures supporting the threshold analysis, broken down to demonstrate the Indian nexus and the worldwide attribution.
• Market and market-share data. Evidence of the relevant product and geographic markets in India, overlaps between the parties, and competitive conditions.
• Internal documents. Board papers, strategic rationale and deal documents that explain the commercial logic of the transaction and its expected effects.

Confidentiality and redaction best practices

Competitively sensitive information requires careful handling. Deal teams should maintain a clear confidentiality strategy: identify genuinely sensitive data, prepare properly reasoned confidentiality requests in line with CCI procedure, and ensure that redactions applied in one jurisdiction are consistent with, and do not undermine, positions taken elsewhere. Over-redaction frustrates the regulator and slows review; under-redaction risks exposing commercially critical information. The goal is a defensible, consistent redaction logic applied across the whole bundle.

How to design a single master bundle for multiple authorities

The master-bundle technique treats every exhibit as a reusable asset. Build a central index of exhibits, each tagged with the jurisdictions in which it will be used, its confidentiality status, and any privilege flag. When a particular authority’s form requires a document, it is drawn from the master set rather than recreated. This mapping discipline is what makes CCI filing coordination genuinely efficient: it ensures that the Indian filing tells the same story as the European and US filings, and that any divergence between filings is deliberate and explicable rather than accidental. For privileged material, maintain a clear privilege log so that disclosure in a jurisdiction that does not recognise the relevant privilege does not inadvertently waive it elsewhere.

Remedies: types, negotiation tactics and CCI acceptance

Where a combination raises competition concerns, remedies become the pivot on which clearance turns. In multi-jurisdiction deals, the remedies question is doubly complex because a package negotiated with one authority must be made to work, or be adapted to work, before others. Understanding how merger remedies india are approached, and how far remedies agreed elsewhere can be relied upon, is central to the strategy.

Common remedies accepted by the CCI

Under Indian practice, parties may offer voluntary modifications to address competition concerns, and the CCI may also propose modifications. The toolkit broadly mirrors international practice:

• Structural divestitures. The sale of a business, brand or asset to a suitable purchaser, removing the overlap that gives rise to the concern. Structural remedies are generally preferred because they are clean and do not require ongoing supervision.
• Behavioural undertakings. Commitments on conduct, such as maintaining supply, licensing on specified terms, or firewalls to prevent information flows. These are typically used where a structural fix is disproportionate.
• Hold-separate arrangements. Interim measures that keep parts of the business independent pending clearance or divestiture, preserving the competitive position while the remedy is implemented.

When the CCI will accept remedies negotiated elsewhere

Deal teams frequently ask whether a remedy package agreed with the European Commission or the US agencies can simply be presented to the CCI. The honest answer is that the CCI conducts its own independent assessment focused on competition in the Indian market. A remedy that resolves a global concern may be a useful starting point, but it will not be rubber-stamped; the CCI will test whether it addresses the specific harm within India.

That said, several practical tactics improve the portability of remedies and increase the likelihood that work done elsewhere carries weight before the CCI. Present clear evidence of how the remedy operates and why it resolves the concern. Where a monitoring trustee has been appointed in another jurisdiction, consider whether that structure can be extended to cover India, reducing duplication. Where the Indian concern is narrower, propose carefully drafted carve-outs that adapt the global package to the Indian market rather than requiring an entirely separate remedy. The aim is to show the CCI that the proposed remedy is effective in India, not merely that it satisfied another authority.

Drafting enforceable remedy language and post-clearance monitoring

A remedy is only as good as its enforceability. Drafting should be precise about scope, timing, the identity and independence of any purchaser or trustee, and the consequences of non-compliance. Ambiguity here is the enemy: vague undertakings invite disputes and prolong post-clearance supervision. Build a monitoring framework into the remedy from the outset, reporting obligations, trustee powers, and defined milestones, so that compliance can be demonstrated objectively. For transactions spanning multiple jurisdictions, align the monitoring mechanisms where possible so that one reporting cycle can satisfy several authorities, reducing the long-term compliance burden on the merged entity.

Timing, suspensions and gun-jumping risk mitigation in India

India’s suspensory regime means a notifiable combination cannot be consummated until it has been cleared or deemed approved. The prohibition on premature implementation, gun-jumping india, is one of the most significant practical risks in cross-border deals, because conduct that is unremarkable in a non-suspensory jurisdiction can expose the parties to penalties and remedial orders in India.

Overview of stand-still rules

The statutory position is that the parties must observe a stand-still until clearance is obtained. In practice, the challenge lies in distinguishing legitimate pre-closing preparation from premature integration. Routine transaction planning is permissible; steps that transfer control, allow the acquirer to direct the target’s commercial conduct, or involve the exchange of competitively sensitive information before clearance are not. The line can be fine, and it is where cross-border deal teams most often stumble because they apply the more permissive norms of other jurisdictions to the Indian leg of the deal. Penalties for consummating a combination before clearance can be significant, as set by the Competition Act and determined by the CCI.

Practical steps to avoid gun-jumping

Concrete measures substantially reduce the risk:

• Hold-separate discipline. Keep the businesses operationally independent until clearance, with no shared decision-making over pricing, strategy or customers.
• Limited integration planning. Confine pre-closing work to planning that does not require implementation; document that integration steps are deferred to completion.
• Data-access protocols. Use clean teams and defined protocols so that any sensitive information exchanged for due diligence is ring-fenced from personnel who set commercial strategy.
• Clear interim covenants. Draft the agreement so that ordinary-course covenants protect value without handing the buyer control before clearance.

Emergency tactics if gun-jumping is suspected

If a deal team suspects that an integration step has crossed the line, swift action matters. Halt the offending conduct immediately, document the facts and the corrective steps taken, and take advice on whether and how to engage the CCI proactively. Early, candid remediation is almost always preferable to waiting for the regulator to raise the issue. Appeals and challenges to CCI orders are heard by the National Company Law Appellate Tribunal (NCLAT), with a further appeal on points of law to the Supreme Court of India. The body of tribunal and court decisions provides important guidance on how enforcement and remedial powers have been exercised in practice, making early advice on exposure all the more valuable.

Practical timeline and execution checklist for deal teams

A disciplined timeline turns the strategy above into execution. The following playbook maps the key milestones for coordinating merger control filings india around a target signing date (T-0). The time references below are illustrative planning markers, not legal deadlines.

Pre-signing phase (T-60 to T-30)

• Run the worldwide threshold and attribution analysis to confirm notifiability in India and all relevant jurisdictions.
• Map competitive overlaps and identify the likely critical-path authority.
• Engage India counsel early, alongside counsel in other key jurisdictions, to agree the sequencing model.
• Begin assembling the master evidence bundle and draft the harmonised disclosure index.
• Assess any interaction with FDI policy and sectoral approvals that could affect timing (DPIIT’s FDI policy and RBI/FEMA cross-border requirements may run in parallel).

Signing to filing (T-0 to T+30)

• Finalise the notification forms for each jurisdiction, drawing from the master bundle.
• Execute the agreed sequencing plan, parallel, staggered, lead-authority or back-loaded.
• Prepare confidentiality and redaction requests consistent across filings.
• Implement hold-separate and clean-team protocols to protect against gun-jumping.

Review and remedies (T+30 onwards)

• Manage information requests, aligning responses across authorities to avoid inconsistency.
• Where remedies are indicated, design a single core package and adapt it for Indian-market concerns.
• Negotiate monitoring and trustee arrangements that can serve multiple jurisdictions.
• Track each authority’s clock and extensions so that no clearance lapses while others remain pending.

Clearance and post-closing

• Confirm all clearances and conditions are satisfied before completion.
• Implement any divestitures or behavioural undertakings on the agreed timetable.
• Maintain post-clearance compliance reporting and trustee oversight.
• Retain a complete record of the filing process in case of later regulatory review.

Conclusion and next steps for deal teams

Coordinating merger control filings india across a multi-jurisdiction transaction in 2026 is an exercise in disciplined sequencing, consistent documentation and realistic remedy planning. The authorities are more assertive about extraterritorial reach, more willing to look at remedies negotiated elsewhere, and unforgiving of premature integration. Deal teams that run the threshold analysis early, choose a sequencing model deliberately, build a single harmonised bundle, and treat gun-jumping as a live risk will close faster and with fewer surprises. The recommended actions are straightforward: confirm notifiability before signing, agree the sequencing plan across all jurisdictions, design remedies once and adapt them to the Indian market, and engage specialist India counsel at the outset rather than once problems emerge.

For transactions touching the Indian market, early coordination is the single highest-value step a deal team can take. This article is general guidance and not legal advice; specific transactions should be reviewed with qualified counsel before any filing strategy is finalised.

Sources

1. Competition Commission of India (CCI), official site
2. Competition Commission of India, combination regulations and notifications
3. National Company Law Appellate Tribunal (NCLAT), official site
4. Ministry of Corporate Affairs (MCA), official site
5. Department for Promotion of Industry and Internal Trade (DPIIT), official portal
6. Reserve Bank of India (RBI), official site
7. OECD, Competition and merger review resources
8. Supreme Court of India, official site